Research programme: immunomodulatory recombinant fusion proteins - Compugen

Drug Profile

Research programme: immunomodulatory recombinant fusion proteins - Compugen

Alternative Names: CGEN 15001 based protein therapeutics; CGEN 15001T based protein therapeutics; CGEN 15021 based protein therapeutics; CGEN 15022 based protein therapeutics; CGEN 15031 based protein therapeutics; CGEN 15051 based protein therapeutics; CGEN 15092 based protein therapeutics; CGEN-15029; CGEN-15029 based protein therapeutics; CGEN-15029/PVRIG; CGEN-15029/TIGIT; CGEN-15052 based protein therapeutics; CGEN-15091 based protein therapeutics; COM 701; COM701/PVRIG

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Compugen
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action CD28 antigen modulators; CD80 antigen modulators; Immunomodulators; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 07 Nov 2017 Compugen plans to file IND with US FDA for COM 902 in 2019
  • 07 Nov 2017 Compugen plans a phase I trial for COM 701 for Cancer (Monotherapy, Combination therapy) in 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top